Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients

M. Rihacek, I. Selingerova, I. Kocak, I. Kocakova, E. Rihackova, D. Valik, J. Sterba

. 2022 ; 29 (6) : 4138-4147. [pub] 20220607

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22018043

Grant support
MMCI 00209805 Ministry of Health
FNBr. 65269705 Ministry of Health
LM2018128 Ministry of Education Youth and Sports
LM201812 Ministry of Education Youth and Sports
MUNI/A/1427/2021 Ministry of Education Youth and Sports

Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an "off-label" option in pediatric oncology. It has been previously reported that sunitinib elevates the mean corpuscular volume of erythrocytes (MCV) in treated subjects. The aim of this study was to assess time-dependent changes of this effect and evaluate its possible clinical relevance. In this study, 179 adult and 21 pediatric patients with solid tumors treated with sunitinib were retrospectively analyzed. The laboratory and treatment-related data were collected for each treatment period. The regression model with a broken-line relationship was used to fit time dependence of the MCV. In the adult group, the MCV was increasing during the first 21.6 weeks (median) of treatment in a median level of 99.8 fL, where it stabilized. MCV increase was faster in the patients who suffered from treatment-related adverse events (21.3 vs. 24.6 weeks, p = 0.010). In the pediatric cohort, the MCV dynamics were similar to adults. In conclusion, MCV changes during sunitinib treatment in pediatric and adult patients may be of clinical utility in monitoring sunitinib treatment course.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018043
003      
CZ-PrNML
005      
20220804134524.0
007      
ta
008      
220720s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/curroncol29060330 $2 doi
035    __
$a (PubMed)35735439
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Rihacek, Michal $u Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Laboratory Medicine, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
245    10
$a Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients / $c M. Rihacek, I. Selingerova, I. Kocak, I. Kocakova, E. Rihackova, D. Valik, J. Sterba
520    9_
$a Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an "off-label" option in pediatric oncology. It has been previously reported that sunitinib elevates the mean corpuscular volume of erythrocytes (MCV) in treated subjects. The aim of this study was to assess time-dependent changes of this effect and evaluate its possible clinical relevance. In this study, 179 adult and 21 pediatric patients with solid tumors treated with sunitinib were retrospectively analyzed. The laboratory and treatment-related data were collected for each treatment period. The regression model with a broken-line relationship was used to fit time dependence of the MCV. In the adult group, the MCV was increasing during the first 21.6 weeks (median) of treatment in a median level of 99.8 fL, where it stabilized. MCV increase was faster in the patients who suffered from treatment-related adverse events (21.3 vs. 24.6 weeks, p = 0.010). In the pediatric cohort, the MCV dynamics were similar to adults. In conclusion, MCV changes during sunitinib treatment in pediatric and adult patients may be of clinical utility in monitoring sunitinib treatment course.
650    _2
$a dospělí $7 D000328
650    12
$a protinádorové látky $x škodlivé účinky $7 D000970
650    12
$a karcinom z renálních buněk $x farmakoterapie $x patologie $7 D002292
650    _2
$a dítě $7 D002648
650    _2
$a erytrocytární znaky $7 D004909
650    _2
$a lidé $7 D006801
650    _2
$a indoly $x škodlivé účinky $7 D007211
650    12
$a nádory ledvin $x farmakoterapie $x patologie $7 D007680
650    _2
$a pyrroly $x škodlivé účinky $7 D011758
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a sunitinib $x farmakologie $x terapeutické užití $7 D000077210
655    _2
$a časopisecké články $7 D016428
700    1_
$a Selingerova, Iveta $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000337133504
700    1_
$a Kocak, Ivo $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Žlutý kopec 7, 625 00 Brno, Czech Republic
700    1_
$a Kocakova, Ilona $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Rihackova, Eva $u Department of Internal Cardiology Medicine, Faculty of Medicine, University Hospital Brno and Masaryk University, Jihlavska 20, 625 00 Brno, Czech Republic
700    1_
$a Valik, Dalibor $u Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic $u Department of Laboratory Medicine, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic $u Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic $1 https://orcid.org/000000030922592X
700    1_
$a Sterba, Jaroslav $u Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic $u The International Clinical Research Centre of St. Anne's University Hospital in Brno, Pekarska 53, 656 91 Brno, Czech Republic
773    0_
$w MED00165427 $t Current oncology (Toronto, Ont.) $x 1718-7729 $g Roč. 29, č. 6 (2022), s. 4138-4147
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35735439 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134518 $b ABA008
999    __
$a ok $b bmc $g 1821895 $s 1169286
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 29 $c 6 $d 4138-4147 $e 20220607 $i 1718-7729 $m Current oncology $n Curr. oncol. $x MED00165427
GRA    __
$a MMCI 00209805 $p Ministry of Health
GRA    __
$a FNBr. 65269705 $p Ministry of Health
GRA    __
$a LM2018128 $p Ministry of Education Youth and Sports
GRA    __
$a LM201812 $p Ministry of Education Youth and Sports
GRA    __
$a MUNI/A/1427/2021 $p Ministry of Education Youth and Sports
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options